RxDoctor Payments DataLook up a doctor →

George Baylor, MD

Pain Medicine · Salem, VANPI 1093806192

Payments from drug & device makers

$23,808in general payments, 2019–2025

Across 794 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • AbbVie$1K
  • Boston Scientific$1K
  • Nevro Corp.$604
  • Collegium Pharmaceutical, Inc.$562
  • Abbott$468
  • plus $4K from 40 others

What the payments were for

  • Speaking & faculty fees$2,99013%
  • Travel & lodging$1,2625%
  • Food & beverage$19,49982%
  • Education$580%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,808 in reported general payments places this provider in the 90th percentile of 150 pain medicine providers in Virginia.

See all pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$820,360
Medicare patients
1,395
Services billed
31,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser16$58,088
BotoxOnabotulinumtoxina35$42,020
Oxycodone Hcl1,206$33,144
Xtampza ErOxycodone Myristate48$30,634
BelbucaBuprenorphine Hcl35$27,891
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen905$25,522
UbrelvyUbrogepant14$24,868
OxycontinOxycodone Hcl36$23,932
Fentanyl128$13,888
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen358$12,919
Buprenorphine38$10,061
Ajovy AutoinjectorFremanezumab-Vfrm13$9,451
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl62$8,379
Gabapentin486$6,856
MovantikNaloxegol Oxalate17$6,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$1,298$66,88849 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$562$58,52583 claims
GRT US Holding, Inc.Qutenza$38$58,08816 claims
Redhill Biopharma Inc.Movantik$19$6,81517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 pain medicine providers in Virginia.

Other pain medicine in Salem

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →